Results 13,881-13,900 of 27,087 for speaker:David Cullinane
- Public Accounts Committee: Business of Committee (8 Nov 2018)
David Cullinane: I do not know whether that is what the Department is accepting. One of the issues we discussed was that its reporting of these issues of overspend was fraud and error. That is the language used. It did not separate them. If it is accepting the recommendation that it should use the term "suspected fraud", that is fine, but that could still be "suspected fraud and error". When we probed...
- Public Accounts Committee: Business of Committee (8 Nov 2018)
David Cullinane: We were not told how they formally report this.
- Public Accounts Committee: Business of Committee (8 Nov 2018)
David Cullinane: Not just in regard to communications. Reporting was the issue.
- Public Accounts Committee: Business of Committee (8 Nov 2018)
David Cullinane: The issue is that journalists or politicians simply pick that global figure and put it out that it is all fraud. That is the point, although I am not pointing fingers at any politician.
- Public Accounts Committee: Business of Committee (8 Nov 2018)
David Cullinane: All of these issues should form part of the Dáil debate we have been seeking.
- Public Accounts Committee: Business of Committee (8 Nov 2018)
David Cullinane: In regard to the request for a Dáil debate, to whom was it recommended?
- Public Accounts Committee: Business of Committee (8 Nov 2018)
David Cullinane: Will it be sent to the Dáil Business Committee?
- Public Accounts Committee: Business of Committee (8 Nov 2018)
David Cullinane: Professor Donnelly states in the correspondence that he is looking forward to appearing before the Committee of Public Accounts to talk to the report. I think he may be referring to the HEA report. At some point, we will receive the special report from the Comptroller and Auditor General and I imagine we will be asking him to appear before us in regard to that report once it has been...
- Public Accounts Committee: Business of Committee (8 Nov 2018)
David Cullinane: We were told that advice was imminent.
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
David Cullinane: I want to follow on from Deputy Connolly. I will come to Mr. Breen first and want to start with CervicalCheck. He said in his opening statement that there were 85 claims, of which 73 were active, five had been settled, one was closed and six were potential claims. The co-defendants are the laboratories. The substance of the awards made in the five settled claims was the misreading of the...
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
David Cullinane: Was there any liability of the State for non-disclosure in any of the settled claims?
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
David Cullinane: Yes, but at that point Mr. Breen was not in a position to give us an estimated cost. Given the passage of time and the fact that there are now five settled claims, can he give us a breakdown of the cost to the State for non-disclosure in the five settled claims?
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
David Cullinane: I know all of that, but------
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
David Cullinane: This concerns accepted liability. I am asking what the cost to the State has been thus far of cases where the State has accepted liability. Surely Mr. Breen is in a position to give me the overall figure for that liability, rather than breaking it down case by case.
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
David Cullinane: Does Mr. Breen not have it at his disposal?
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
David Cullinane: Can he give it to us during the course of the day? I could ask for a second speaking slot if so.
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
David Cullinane: I am talking about the State's liability in settled cases concerning non-disclosure, not upon a case-by-case basis but the overall sum.
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
David Cullinane: This briefing note, which is very good, includes a breakdown of the overall number of active claims, broken down into bands up to €1 million, €1 million to €4 million and so on, and the amount involved. That is quite helpful. There are 3,365 claims, with an estimated liability of €3.57 billion. Is that correct?
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
David Cullinane: Do those 3,365 active claims include the 85 CervicalCheck claims?
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
David Cullinane: Can Mr. Breen give us the overall estimated liability for those 85 claims?